SEARCH

SEARCH BY CITATION

References

  • 1
    Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free β-human chorionic gonadotropin and pregnancy associated plasma protein-A. Ultrasound Obstet Gynecol 1999; 13: 231237.
  • 2
    Tul N, Spencer K, Noble P, Chan C, Nicolaides KH. Screening for trisomy 18 by fetal nuchal translucency thickness and maternal serum free β-hCG and pregnancy associated plasma protein-A at 10–14 weeks of gestation. Prenat Diagn 1999; 19: 10351042.
  • 3
    Spencer K, Ong C, Skentou H, Liao AW, Nicolaides KH. Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta-hCG and pregnancy associated plasma protein-A at 10–14 weeks of gestation. Prenat Diagn 2000; 20: 411416.
  • 4
    Spencer K, Liao AW, Skentou H, Cicero S, Nicolaides KH. Screening for triploidy by fetal nuchal translucency and maternal serum free β-human chorionic gonadotropin and pregnancy associated plasma protein-A at 10–14 weeks of gestation. Prenat Diagn 2000; 20: 495499.
  • 5
    Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience. BJOG 2003; 110: 281286.
  • 6
    Avgidou K, Papageorghiou A, Bindra R, Spencer K, Nicolaides KH. Prospective first-trimester screening for trisomy 21 in 30,564 pregnancies. Am J Obstet Gynecol 2005; 192: 17611767.
  • 7
    Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O. Mutlitcenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 2005; 25: 221226.
  • 8
    Ong CYT, Liao AW, Spencer K, Munim S, Nicolaides KH. First trimester maternal serum free β human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. BJOG 2000; 107: 12651270.
  • 9
    Steer P. The epidemiology of preterm labour. BJOG 2005; 112 (Suppl 1): 13.
  • 10
    Marlowe N, Wolke D, Bracewell MA, Samara N. Neurological and developmental disability at six years of age after extremely preterm birth. N Engl J Med 2005; 352: 919.
  • 11
    Veen S, Ens-Dokkum MH, Schreuder AM, Verloove-Vanhorick SP, Brand R, Ruys JH. Impairments, disabilities, and handicaps of very preterm and very-low-birthweight infants at five years of age. The Collaborative Project on Preterm and Small for Gestational Age Infants (POPS) in The Netherlands. Lancet 1991; 338: 3336.
  • 12
    Petrou S. The economic consequences of preterm birth during the first 10 years of life. BJOG 2005; 112 (Suppl 1): 1015.
  • 13
    Spencer K, Bindra R, Nix ABJ, Heath V, Nicolaides KH. Delta-NT or NT MoM: which is the most appropriate method for calculating accurate patient-specific risks for trisomy 21 in the first trimester? Ultrasound Obstet Gynecol 2003; 22: 142148.
  • 14
    Snijders RJM, Sundberg K, Holzgreve W, Henry G, Nicolaides KH. Maternal age- and gestation-specific risk for trisomy 21. Ultrasound Obstet Gynecol 1999; 13: 167170.
  • 15
    Spencer K, Ong CYT, Liao AWK, Nicolaides KH. The influence of ethnic origin on first trimester biochemical markers of chromosomal anomalies in the first trimester. Prenat Diagn 2000; 20: 491494.
  • 16
    Spencer K, Bindra R, Nicolaides KH. Maternal weight correction of maternal serum PAPP-A and free β-hCG when screening for trisomy 21 in the first trimester of pregnancy. Prenat Diagn 2003; 23: 851855.
  • 17
    Spencer K, Bindra R, Cacho AM, Nicolaides KH. The impact of smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy. Prenat Diagn 2004; 24: 169173.
  • 18
    Spencer K, Heath V, El-Sheikhah A, Ong CYT, Nicolaides KH. Ethnicity and the need for correction of biochemical and ultrasound markers of chromosomal anomalies in the first trimester: a study of Oriental, Asian and Afro-Caribbean populations. Prenat Diagn 2005; 25: 365369.
  • 19
    Snijders RJM, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk for trisomy 21 by maternal age and fetal nuchal translucency thickness at 10–14 weeks of gestation. Lancet 1998; 18: 519521.
  • 20
    Yudkin PL, Aboualfa M, Eyre JA, Redman CW, Wilkinson AR. New birth weight and head circumference centiles for gestational ages 24 to 42 weeks. Early Hum Dev 1987; 15: 4552.
  • 21
    Cowans NJ, Spencer K. First-trimester ADAM12 and PAPP-A as markers for intrauterine fetal growth restriction through their roles in the insulin-like growth factor system. Prenat Diagn 2007; 27: 264271.
  • 22
    Spencer K, Cowans NJ, Avgidou K, Nicolaides KH. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death. Ultrasound Obstet Gynecol 2006; 28: 637643.
  • 23
    Spencer K, Cowans NJ, Avgidou K, Molina F, Nicolaides KH. First-trimester biochemical markers of aneuploidy and the prediction of small-for-gestational age fetuses. Ultrasound Obstet Gynecol 2007. DOI: 10.1002/uog.5165.
  • 24
    Spencer K, Yu CK, Cowans NJ, Otigbah C, Nicolaides KH. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. Prenat Diagn 2005; 25: 949953.
  • 25
    Smith GCS, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. Early pregnancy levels of pregnancy-associated plasma protein-A and the risk of intrauterine growth restriction, premature birth, preeclampsia and stillbirth. J Clin Endocrinol Metab 2002; 87: 17621767.
  • 26
    Dugoff L, Hobbins JC, Malone FD, Porter TF, Luthy D, Comstock CH, Hankins G, Berkowitz RL, Merkatz I, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Vidaver J, D'Alton ME. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol 2004; 191: 14461451.
  • 27
    Krantz D, Goetzl L, Simpson JL, Thom E, Zachary JM, Hallahan TW, Silver R, Pergament E, Platt LD, Filkins K, Johnson A, Mahoney M, Hogge WA, Wilson RD, Mohide P, Hershey D, Wapner RJ. First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. Association of extreme first-trimester free human chorionic gonadotropin-β, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol 2004; 191: 14521458.
  • 28
    Gyetvai K, Hannah ME, Hodnett ED, Ohlsson A. Tocolytics for preterm labor: a systematic review. Obstet Gynecol 1999; 94: 869877.
  • 29
    Sanchez-Ramos L, Kaunitz AM, Delke I. Progesterone agents to prevent preterm birth: A meta-analysis of randomized controlled trials. Obstet Gynecol 2005; 105: 273279.
  • 30
    To MS, Skentou CA, Royston P, Yu CKH, Nicolaides KH. Prediction of patient-specific risk of early preterm delivery using maternal history and sonographic measurement of cervical length: a population-based prospective study. Ultrasound Obstet Gynecol 2006; 27: 362367.
  • 31
    Yaron Y, Heifetz S, Ochshorn Y, Lehavi O, Orr-Urtreger A. Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome. Prenat Diagn 2002; 22: 778782.
  • 32
    Santolaya-Forgas J, De Leon JA, Cullen Hopkins R, Castracane VD, Kauffman RP, Sifuentes GA. Low pregnancy-associated plasma protein-A at 10 + 1 to 14 + 6 weeks of gestation and a possible mechanism leading to miscarriage. Fetal Diagn Ther 2004; 19: 456461.
  • 33
    De Leon J, Sifuentes G, Hopkins C, Noble V, Gimpel T, Myles T, Santolaya-Forgas J. Maternal serum free β-hCG levels in uncomplicated pregnancies at the 10th–15th week of gestation and the development of obstetric complications. J Reprod Med 2004; 49: 8992.
  • 34
    Morssink LP, Kornman LH, Hallahan TW, Kloosterman MD, Beekhuis JR, de Wolf BTHM, Mantingh A. Maternal serum levels of free β-hCG and PAPP-A in the first trimester of pregnancy are not associated with subsequent fetal growth retardation or preterm delivery. Prenat Diagn 1998; 18: 147152.
  • 35
    Tul N, Pusenjak S, Osredkar J, Spencer K, Novak-Antolic Z. Predicting complications of pregnancy with first-trimester maternal serum free β-hCG, PAPP-A and inhibin-A. Prenat Diagn 2003; 23: 990996.